Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Other Events
Item 8.01. Other Events.
On February 16, 2017, Neuralstem, Inc. (the Company) announced
the completion of subject enrollment in its Phase 2 clinical
trial of NSI-189 for the treatment of major depressive disorder.
A copy of the press release is attached to this report as Exhibit
99.01.
Item 9.01. Financial Statements and Exhibits.
| Exhibit No. | Description |
| 99.01 | Press Release Dated February 16, 2017 |
About Neuralstem, Inc. (NASDAQ:CUR)
Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. (NASDAQ:CUR) Recent Trading Information
Neuralstem, Inc. (NASDAQ:CUR) closed its last trading session up +0.59 at 3.77 with 3,603,513 shares trading hands.